Redefining Metabolic Dysfunction-Associated Steatohepatitis Treatment: Managed Care Insights on New Therapies Targeting Metabolic Dysfunction

Program Description

Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive, inflammatory liver disease that represents the most severe form of metabolic dysfunction–associated steatotic liver disease (MASLD). Driven by the accumulation of fat in the liver and other metabolic disturbances, MASH can advance to fibrosis, cirrhosis, hepatocellular carcinoma, and end-stage liver failure. Because MASH is often asymptomatic until advanced stages, early testing and accurate identification of at-risk individuals are crucial to prevent progression and improve long-term outcomes. This program will equip pharmacists and managed care professionals with up-to-date knowledge on MASH pathophysiology, clinical presentation, and disease burden, alongside emerging data from pivotal clinical trials of approved and investigational therapies. Participants will explore recent guideline updates and evidence-based, personalized treatment approaches tailored to disease severity, comorbidities, and patient-specific factors. The program will also address the rapidly evolving therapeutic landscape, the importance of early identification and intervention, and managed care strategies to optimize access, outcomes, and health care resource utilization.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: June 29, 2026
Expiration date: June 29, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the metabolic drivers of metabolic dysfunction-associated steatohepatitis (MASH), along with its key clinical manifestations, common comorbid conditions, diagnostic evaluation, and overall impact on disease burden.
• Interpret current data and guideline recommendations underpinning FDA-approved therapies for MASH as well as the mechanisms of action of late-stage investigational agents.
• Apply managed care strategies that facilitate timely diagnosis and equitable access to evidence-based MASH treatments, with the goal of improving clinical outcomes and mitigating downstream health care costs.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-26-193-H01-P. The activity is available for CE credit through June 29, 2027

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Drake Reiter, PharmD, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Capvision, COEUS, Health Institutes Research Center, Herspiegel, Eversana, MMIT, Precision AQ

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:

ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms